SCI时时刷

search
+
Correspondence on 'Cardiovascular toxicities associated with bispecific T-cell engager therapy' by Sayed et al
We read with great interest the research article by Sayed et al.1 Although it is very useful to understand the utilization...
Total metabolic tumor volume on 18F-FDG PET/CT is a game-changer for patients with metastatic lung cancer treated with immunotherapy
IntroductionNon-small-cell lung cancers (NSCLC) account for 80% of lung cancers, which is the leading cause of cancer-rela...
Response to: Correspondence on 'Cardiovascular toxicities associated with bispecific T-cell engager therapy' by Noguchi et al
We would like to thank Dr Noguchi and his colleagues for their comments regarding our paper Cardiovascular toxicities asso...
Tumor-agnostic transcriptome-based classifier identifies spatial infiltration patterns of CD8+T cells in the tumor microenvironment and predicts clinical outcome in early-phase and late-phase clinical trials
IntroductionCancer immunotherapy (CIT) has been widely integrated into routine clinical practice for many tumor indication...
Association of metabolomics with PD-1 inhibitor plus chemotherapy outcomes in patients with advanced non-small-cell lung cancer
IntroductionIn recent years, the treatment landscape for non-small cell lung cancer (NSCLC) lacking driver gene mutations ...
Society for Immunotherapy of Cancer (SITC) recommendations on intratumoral immunotherapy clinical trials (IICT): from premalignant to metastatic disease
Common considerationsWhen considering the current state of intratumoral immunotherapy for advanced cancer, the lack of pha...
Dysregulation of CD4+ and CD8+ resident memory T, myeloid, and stromal cells in steroid-experienced, checkpoint inhibitor colitis
ResultsA multiomic workflow to study CPI colitisTo study checkpoint inhibitor-induced colitis (CPI colitis) through an unb...
Phase 1a dose escalation study of ivonescimab (AK112/SMT112), an anti-PD-1/VEGF-A bispecific antibody, in patients with advanced solid tumors
WHAT IS ALREADY KNOWN ON THIS TOPICWHAT THIS STUDY ADDSIvonescimab (AK112) is a first-in-class, humanized tetravalent bisp...
Preclinical evaluation of two phylogenetically distant arenavirus vectors for the development of novel immunotherapeutic combination strategies for cancer treatment
BackgroundHigh-risk human papillomavirus (HPV) is one of the main causes of infection-related cancers and a major risk fac...
Tumor-targeted therapy with BRAF-inhibitor recruits activated dendritic cells to promote tumor immunity in melanoma
IntroductionMelanoma comprises a small fraction of all cutaneous malignancies but is responsible for the majority of skin ...
Germline homozygosity and allelic imbalance of HLA-I are common in esophagogastric adenocarcinoma and impair the repertoire of immunogenic peptides
IntroductionClassical human leucocyte antigen class I molecules (HLA-A, HLA-B, and HLA-C) are expressed by somatic cells a...
Tetracyclines enhance antitumor T-cell immunity via the Zap70 signaling pathway
BackgroundCancer immunotherapy including immune checkpoint inhibitors (ICIs) is only beneficial for a limited population o...
Efficacy of LCMV-based cancer immunotherapies is unleashed by intratumoral injections of polyI:C
BackgroundLymphocytic choriomeningitis virus (LCMV) is an RNA virus that belongs to the Arenavirus family.1 The primary ho...
Combinational therapy of CAR T-cell and HDT/ASCT demonstrates impressive clinical efficacy and improved CAR T-cell behavior in relapsed/refractory large B-cell lymphoma
IntroductionAlthough approximately 60% of patients with large B-cell lymphoma (LBCL) achieve long-term remission after fir...
Immunotherapy-based regimens for patients with EGFR-mutated non-small cell lung cancer who progressed on EGFR-TKI therapy
IntroductionEpidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) are the standard of care for patients ...
B cells and the coordination of immune checkpoint inhibitor response in patients with solid tumors
The first clinical observations hinting at a host-dependent antitumor immunity date back from more than 150 years ago, wit...
Spatial comparison of molecular features associated with resistance to pembrolizumab in BCG unresponsive bladder cancer
IntroductionBCG is the primary treatment for high-risk non-muscle invasive bladder cancer (NMIBC).1 Yet, at least one-thir...
Preclinical evaluation and first-in-dog clinical trials of PBMC-expanded natural killer cells for adoptive immunotherapy in dogs with cancer
WHAT IS ALREADY KNOWN ON THIS TOPICNatural killer (NK) cell adoptive transfer has the potential to overcome barriers to su...
Armored TGF{beta}RIIDN ROR1-CAR T cells reject solid tumors and resist suppression by constitutively-expressed and treatment-induced TGF{beta}1
BackgroundAutologous chimeric antigen receptor (CAR) T-cell therapy has revolutionized treatment for patients with B-cell ...
Phase 1 study combining elotuzumab with autologous stem cell transplant and lenalidomide for multiple myeloma
WHAT IS ALREADY KNOWN ON THIS TOPICWhile autologous stem cell transplantation (ASCT) enhances disease-free survival in new...
Efficient CAR T cell targeting of the CA125 extracellular repeat domain of MUC16
IntroductionOvarian cancer (OC) is the eighth most common cancer in women globally, for both incidence and deaths,1 with a...
Autologous human preclinical modeling of melanoma interpatient clinical responses to immunotherapeutics
BackgroundMelanoma is one of the most responsive malignancies to immunotherapy, including PD-1 and CTLA-4 inhibitors.1 2 H...
Respiratory complex I regulates dendritic cell maturation in explant model of human tumor immune microenvironment
IntroductionWhile a common denominator of cancer is a dysregulation of the tumor immune microenvironment (TIME), the actua...
Treatment-free survival outcomes from the phase II study of nivolumab and salvage nivolumab/ipilimumab in advanced clear cell renal cell carcinoma (HCRN GU16-260-Cohort A)
WHAT IS ALREADY KNOWN ON THIS TOPICSignificant treatment-free survival (TFS) has been reported for the nivolumab/ipilimuma...
Oral PD-L1 inhibitor GS-4224 selectively engages PD-L1 high cells and elicits pharmacodynamic responses in patients with advanced solid tumors
IntroductionThe inhibitory receptor programmed cell death 1 (PD-1) is a key negative regulator of T-cell function that act...
Longitudinal analysis of PD-L1 expression in patients with relapsed NSCLC
IntroductionLung cancer is the leading cause of cancer-associated mortality in Western nations.1 Non-small cell lung cance...
OMA1 competitively binds to HSPA9 to promote mitophagy and activate the cGAS-STING pathway to mediate GBM immune escape
BackgroundGlioma represents the prevailing primary malignant neoplasm within the central nervous system tumors, with gliob...
Dual molecule targeting HDAC6 leads to intratumoral CD4+ cytotoxic lymphocytes recruitment through MHC-II upregulation on lung cancer cells
WHAT IS ALREADY KNOWN ON THIS TOPICAlterations in histone deacetylase (HDAC) expression and activity have been documented ...
Oncolytic herpes simplex virus expressing IL-2 controls glioblastoma growth and improves survival
IntroductionGlioblastoma (GBM), the most common primary malignant brain tumor, is highly immunosuppressive and has no effe...
Do galectins serve as soluble ligands for immune checkpoint receptors?
Galectins are a family of soluble glycan-binding proteins containing one or two highly conserved carbohydrate recognition ...
阅读更多
format_indent_increase